NanoLogix Inc. and University of Texas Medical Center Shortening Wait Times For Group-B Streptococcus Lab Tests, With Potential Market of 4.3 Million Tests A YearEarly Results Show NanoLogix BNF Technology Detects Group-B Strep At Least 12 Times Faster
HUBBARD, Ohio, May 18, 2010 /PRNewswire-FirstCall via COMTEX/ -- NanoLogix, Inc. (Pink Sheets: NNLX) announced today the application of its BNF technology by the University of Texas-Texas Medical Center in controlled testing for the bacteria Group B Streptococcus (GBS) in pregnant women.¬† Early results show NanoLogix BNF technology detects GBS in roughly two to six hours, as opposed to traditional Petri culture methods, which can take 72 hours or longer. Texas Medical Center physicians see the high-speed diagnostic capabilities of the NanoLogix technology as a key to faster detection of GBS in late term pregnancies and a reduction in the over use of antibiotics as an precautionary measure.
The Center for Disease Control (CDC) recommends all pregnant women be tested for GBS, amounting to roughly 4.3 million tests each year annually in the U.S. CDC guidelines recommend physicians test pregnant women for GBS in the final weeks of their term. Roughly 30 percent of reproductive-age women carry GBS. If mothers carrying GBS deliver before they are treated, the lives of newborns can be seriously endangered. The long wait times of traditional Petri culture technology (72 hours) puts infants at risk of being delivered before results come back. This increases the use of antibiotics, as a precautionary measure.
Physicians and staff at the University of Texas - Texas Medical Center in Houston began to experiment with obstetrics applications for NanoLogix BNF technology in September 2009. This week Medical Center personnel are undertaking work to determine the smallest amount of Group B Streptococcus (GBS) identifiable and the shortest test time achievable through the use of NanoLogix BNF technology.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in a multitude of infectious and non-infectious human diseases, including but not limited to tuberculosis, non-tuberculous mycobacterium (NTM), pneumonia, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation. For more information visit www.nanologix.com.
Lisa Ann Pinkerton
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Copyright 2010 NanoLogix, Inc All Rights Reserved